mTOR inhibitors: changing landscape of endocrine-resistant breast cancer (Q38190114)

30 August 2017

1 reference

title

mTOR inhibitors: changing landscape of endocrine-resistant breast cancer (English)

1 reference

30 August 2017

2

1 reference

30 August 2017

Saranya Chumsri

1

1 reference

30 August 2017

Katherine Tkaczuk

series ordinal

3

1 reference

30 August 2017

Angela Brodie

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

10

1 reference

30 August 2017

443-456

1 reference

30 August 2017

3

1 reference

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole

30 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Selective estrogen-receptor modulators and antihormonal resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

New strategies in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Control of p70 s6 kinase by kinase activity of FRAP in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Therapeutic potential of target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Phospholipase D confers rapamycin resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

Aromatase, aromatase inhibitors, and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.178

21 January 2018

Identifiers

DOI

10.2217/FON.13.178

1 reference

30 August 2017

1 reference